Frankfurt
21.07.26 | 08:07
0,078 Euro
-2,14 % -0,002
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.06. | Diamyd Medical AB (publ): Mathias Skalmstad new CFO at Diamyd Medical | 135 | GlobeNewswire (Europe) | Diamyd Medical is pleased to announce that Mathias Skalmstad will take up the position of Chief Financial Officer at Diamyd Medical as early as July 1st, 2026.
"With my extensive experience from both... ► Artikel lesen | |
| 24.06. | Diamyd Medical AB Ser. B Q3 Loss Climbs | 1 | RTTNews | ||
| 24.06. | Diamyd Medical AB (publ): Quarterly Report 3 25/26 | 163 | GlobeNewswire (Europe) | September 2025 - May 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes... ► Artikel lesen | |
| 23.06. | Diamyd Medical AB (publ): Diamyd Medical provides update on Strategic Review | 186 | GlobeNewswire (Europe) | Following the outcome of the DIAGNODE-3 study, the Company's immediate priority is to complete the close-out of the Phase 3 program in an efficient and responsible manner.
Upon completion of this process... ► Artikel lesen | |
| 18.06. | Diamyd Medical AB (publ): Diamyd Medical announces update regarding interim CFO | 141 | GlobeNewswire (Europe) | Diamyd Medical today announces that Anna Styrud, appointed interim CFO in Diamyd Medical, will not be able to start her position as previously communicated due to changes in her availability. A review... ► Artikel lesen | |
| 11.06. | Diamyd Medical AB (publ): Diamyd Medical receives Notice of Allowance for Key Precision Medicine Patent | 156 | GlobeNewswire (Europe) | Diamyd Medical has been given notice that the USPTO has allowed a patent application and is expected to proceed to grant a patent protecting the use of retogatein (GAD65) to treat individuals with type... ► Artikel lesen | |
| 05.06. | Diamyd Medical AB (publ): Diamyd Medical provides update on ongoing Activities | 158 | GlobeNewswire (Europe) | Diamyd Medical today announced that it, as part of an ongoing strategic review, has received several proposals from external parties, including formal non-binding Letters of Intent, as well as invitations... ► Artikel lesen | |
| 22.05. | Diamyd Medical AB (publ): Diamyd Medical announces that Niklas Axelsson has decided to leave his position as CFO to take on a new role in another company | 181 | GlobeNewswire (Europe) | A review to find a successor will now begin, and Niklas will remain with the company for some time to enable a handover to this person.
"Although Niklas has worked for Diamyd for a relatively short... ► Artikel lesen | |
| DIAMYD MEDICAL Aktie jetzt für 0€ handeln | |||||
| 20.05. | Diamyd Medical AB (publ): Diamyd Medical receives GMP certification and manufacturing authorization for biological investigational medicinal products for human use | 245 | GlobeNewswire (Europe) | Diamyd Medical today announced a significant advancement in the company's operations related to the manufacturing of biological medicines (biologics). The company has now received GMP (Good Manufacturing... ► Artikel lesen | |
| 11.05. | Diamyd Medical AB (publ): Diamyd Medical provides an update on strategic review and financial position | 321 | GlobeNewswire (Europe) | Diamyd Medical today announces that the initial phase of the strategic review, initiated following the discontinuation of the Phase 3 DIAGNODE-3 trial, has been completed.
Strategic review update
The... ► Artikel lesen | |
| 24.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership update | 260 | GlobeNewswire (Europe) | Further to the Company's press release regarding governance changes following the March 27 interim analysis of its DIAGNODE-3 study, Diamyd Medical today announces that Chairman Anders Essen-Möller... ► Artikel lesen | |
| 23.04. | Diamyd Medical AB (publ): Diamyd Medical announces governance and leadership changes | 254 | GlobeNewswire (Europe) | Following Diamyd Medical's unexpectedly negative results from the March 27 interim analysis of its DIAGNODE-3 study, the Board of Directors has implemented governance changes to strengthen oversight... ► Artikel lesen | |
| 10.04. | Diamyd Medical AB (publ): Diamyd Medical discontinues DIAGNODE-3 following evaluation confirming futility; initiates strategic review | 580 | GlobeNewswire (Europe) | Diamyd Medical today announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes. Following the previously reported interim analysis and... ► Artikel lesen | |
| 08.04. | Diamyd Medical AB (publ): Bulletin from Diamyd Medical's Extraordinary General Meeting 2026 | 416 | GlobeNewswire (Europe) | An Extraordinary general meeting of Diamyd Medical Aktiebolag (the "Company") was held on April 8, 2026.
The Extraordinary General Meeting resolved to approve the board of directors' resolution from... ► Artikel lesen | |
| 29.03. | Diamyd Medical AB (publ): Diamyd Medical updates on the interim efficacy analysis of Phase 3 DIAGNODE-3 trial | 455 | GlobeNewswire (Europe) | Diamyd Medical on Friday March 27th announced that the pre-specified interim efficacy analysis on 174 out of 321 participants of the ongoing Phase 3 DIAGNODE-3 trial yielded results that were unexpected... ► Artikel lesen | |
| 27.03. | Diamyd Medical AB: Diamyd Medical reports negative interim results of Phase 3 DIAGNODE-3 trial | 540 | GlobeNewswire (Europe) | Diamyd Medical today announced the completion of a pre-specified interim efficacy analysis on C-peptide in the ongoing pivotal Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in individuals... ► Artikel lesen | |
| 25.03. | Diamyd Medical AB: Quarterly Report 2 25/26 | 377 | GlobeNewswire (Europe) | September 2025 - February 2026, Diamyd Medical AB (publ), Fiscal year 2025/2026
Precision Medicine for type 1 diabetes
Fully enrolled registrational Phase 3 program
Diamyd Medical develops a... ► Artikel lesen | |
| 23.03. | Diamyd Medical AB: Notice Of Extraordinary General Meeting In Diamyd Medical Aktiebolag | 6 | Cision News | ||
| 23.03. | Diamyd Medical AB: Diamyd Medical enters into equity financing agreements with new U.S. sector specialist investors for up to USD 125 million and announces full enrollment in Phase 3 trial | 590 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND... ► Artikel lesen | |
| 19.03. | Diamyd Medical AB: Diamyd Medical receives Notice of Grant in Japan for insulin-based antigen therapy patent in type 1 diabetes | 269 | GlobeNewswire (Europe) | Diamyd Medical has received a Notice of Grant in Japan for a patent covering the use of insulin-based antigens to treat individuals with type 1 diabetes who carry the HLA DR4-DQ8 genetic marker. Once... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 47,620 | +0,32 % | Heftige Ausschläge im LifeScience-Sektor! Bayer, Vidac Pharma, BioNTech, Moderna und Evotec im Brennpunkt | Hier geht's rund! Aktuell erlebt die Krebsforschung durch die Verschmelzung von Zellanalyse und digitaler Präzision eine historische Zeitenwende. Mit einem neuen Management versucht BioNTech seine revolutionäre... ► Artikel lesen | |
| NOVO NORDISK | 43,495 | +0,07 % | Johnson & Johnson, GSK und Co.: Warum der Wettlauf um Zelltherapie-Plattformen gerade erst beginnt | ||
| PFIZER | 21,850 | +0,78 % | BioNTech und Pfizer werden zum geopolitischen Pharmafall | Die gemeinsame Entwicklung des Corona-Impfstoffs galt als Musterbeispiel globaler Arbeitsteilung: deutsche mRNA-Forschung, amerikanische Pharmakapazitäten, internationale Produktion und staatlich organisierte... ► Artikel lesen | |
| ABBVIE | 224,00 | +0,90 % | Dividendenbekanntmachungen (15.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,63 USD 0,5516 EUR ABBOTT LABORATORIES CDR CA0028221046 0,1102 CAD 0,0686 EUR ABBVIE INC US00287Y1091 1... ► Artikel lesen | |
| ROCHE | 361,45 | +1,52 % | Roche Appoints Dan Malarek as President and CEO of Roche Diagnostics North America | Dan Malarek, current CEO of Foundation Medicine Inc., appointed President and CEO of Roche Diagnostics North America, effective August 1, 2026
Malarek succeeds... ► Artikel lesen | |
| MERCK & CO | 110,46 | +1,36 % | Merck & Co erhält US-Zulassung für neuartige Cholesterin-Pille | DJ Merck & Co erhält US-Zulassung für neuartige Cholesterin-Pille
Von Peter Loftus
DOW JONES--Die US-Arzneimittelbehörde FDA hat eine neuartige Pille von Merck & Co zugelassen, die den Cholesterinspiegel... ► Artikel lesen | |
| ABBOTT LABORATORIES | 87,34 | -1,95 % | Benchmark reiterates Buy on Abbott Labs stock, cites guidance raise | ||
| DERMAPHARM | 41,600 | -2,23 % | Finanzaufsicht Bafin untersucht Jahresabschluss von Dermapharm | FRANKFURT (dpa-AFX) - Die Finanzaufsicht Bafin hat eine Prüfung des Jahresabschlusses und des Lageberichts des Arzneimittelherstellers Dermapharm für das Jahr 2025 eingeleitet. Es lägen konkrete Anhaltspunkte... ► Artikel lesen | |
| ZOETIS | 65,92 | -1,23 % | Dividendenbekanntmachungen (20.07.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADENTRA INC CA00686A1084 0,16 CAD 0,0997 EUR BUERGERLICHES BRAUHAUS RAVENSBURG-LINDAU ... DE0005281000 - 10 EUR CATERPILLAR INC US1491231015 1... ► Artikel lesen | |
| DOCMORRIS | 11,640 | +2,74 % | Ihre wichtigsten Termine: Johnson & Johnson, DocMorris, PNC Financial Services mit neuen Quartalszahlen! | © Foto: Christian Charisius - dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine... ► Artikel lesen | |
| EYEPOINT | 11,300 | +1,80 % | EyePoint, Inc. - 8-K, Current Report | ||
| PENTIXAPHARM | 2,250 | +5,63 % | Pentixapharm: Hypertension, re-imaged; INITIATE with BUY: PentixaFor turns a niche, invasive test into a scalable ... | A major diagnostic market opening. Pentixapharm is the way to play it.In July 2025, Endocrine Society delivered the most consequential catalyst for Pentixapharm's late-stage diagnostic asset PentixaFor.... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 195,60 | +0,80 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy | FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment... ► Artikel lesen | |
| DAIICHI SANKYO | 15,598 | +3,50 % | EQS-News: Daiichi Sankyo Deutschland GmbH: Bundesgesundheitsministerin Warken besucht Produktions- und Entwicklungsstandort von Daiichi Sankyo in Pfaffenhofen | EQS-News: Daiichi Sankyo Deutschland GmbH
/ Schlagwort(e): Stellungnahme/Studie
Bundesgesundheitsministerin Warken besucht Produktions- und Entwicklungsstandort von Daiichi Sankyo... ► Artikel lesen | |
| TRULIEVE CANNABIS | 7,830 | +3,71 % | Drama um Canopy, Tilray & Co?: Anhörungsprozess zu Cannabis endet - Stürzt die DEA den Sektor ins Chaos? | © Foto: adobe.stock.comAm 29. Juni begann der Anhörungsprozess der DEA zur möglichen Neueinstufung von Freizeit-Cannabis in Schedule III. Mittlerweile steht der Anhörungsprozess vor seinem Ende. Was... ► Artikel lesen |
DIAMYD MEDICAL AB gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell -2,14 % bei einem Aktienkurs von 0,078 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAMYD MEDICAL AB finden Sie auf Wallstreet Online.